The Effect of Probiotics on Chronic Kidney Disease
1 other identifier
interventional
148
1 country
1
Brief Summary
Probiotics could attenuate renal function deterioration in CKD patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started May 2017
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 23, 2017
CompletedFirst Submitted
Initial submission to the registry
July 21, 2017
CompletedFirst Posted
Study publicly available on registry
July 25, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 19, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
April 30, 2022
CompletedJuly 21, 2022
July 1, 2022
4.2 years
July 21, 2017
July 20, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
eGFR decline rate.
Compare estimated glomerular filtration rate decline rate within baseline, 3, 6, 9 and 12 months after taking probiotics.
12 months.
Secondary Outcomes (3)
Change rate in serum pro-inflammatory cytokines (TNF-α, IL6 and IL18) and endotoxin.
12 months
Average scores of gastrointestinal symptoms by questionnaire.
12 months.
Relative abundance of intestinal microbiota.
12 months.
Study Arms (2)
Probiotics
EXPERIMENTALTaking two capsules of probiotics twice daily for 12 months.
Healthy control
NO INTERVENTIONHealthy volunteers were: no hypertension (Blood pressure\<140/90mmHg), no diabetes (Glucose AC 70\~100mg/dl), no hyperlipidemia (Cholesterol Total 130\~200mg/dL、Triglyceride\<150mg/dL), no urinary protein (-) and normal renal function (eGFR\>90), after signing the consent form, the stool samples will be collected.
Interventions
CKD Patients were supplemented with two capsules of probiotics containing 2.5\*10\^9 CFU Lactobacillus acidophilus (TYCA06), Bifidobacterium longum (BLI-02) and Bifidobacterium bifidum (VDD088) twice daily for 12 months.
Eligibility Criteria
You may qualify if:
- ‧Stage 3-5 CKD patients, at least 20 years of age and regular follow-up for at least 6 months prior to enrollment.
You may not qualify if:
- Pregnancy.
- On immunosuppressive therapy.
- Active infectious condition.
- Acute kidney injury.
- Consuming other forms of probiotics.
- Taking antibiotics within 30 days prior to enrollment.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
China Medical University Hospital
Taichung, 413, Taiwan
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
I-kuan Wang
China Medical University Hospital
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Attending physician
Study Record Dates
First Submitted
July 21, 2017
First Posted
July 25, 2017
Study Start
May 23, 2017
Primary Completion
August 19, 2021
Study Completion
April 30, 2022
Last Updated
July 21, 2022
Record last verified: 2022-07